Empower Pharmacy

Empower is one of the larger names in US compounding, operating as both a patient-specific 503A pharmacy and an FDA-registered 503B outsourcing facility. That dual status is the thing to understand first: the same company can prepare a one-off patient prescription (503A) and manufacture larger office-use batches under CGMP (503B).

Facility & accreditation

Empower appears on the FDA’s Registered Outsourcing Facilities (503B) list as “Empower Pharma, Houston, TX” (initial registration July 16, 2016), with a related “Empower Clinic Services” entity registered in East Windsor, NJ ^[1]. The company describes itself as a 503A compounding pharmacy and 503B outsourcing facility and says it is licensed to ship nationwide, including Puerto Rico ^[2].

We independently confirmed Empower’s PCAB accreditation in ACHC’s own accredited-organization directory (ACHC administers PCAB): “Empower Clinic Services, LLC / Empower Pharmacy,” Houston, TX, holds PCAB Compounding Pharmacy accreditation valid January 10, 2026 – January 9, 2029, covering non-sterile (USP <795>), sterile (USP <797>), and hazardous-drug (USP <800>) compounding ^[3]. The site also shows a LegitScript certification, which we did not independently verify (LegitScript’s per-domain checker is access-gated).

What they compound

Relevant to peptide and metabolic care: compounded GLP-1s (semaglutide, tirzepatide), a dedicated peptide line (including sermorelin and GHK-Cu), testosterone/HRT, HCG, NAD+, and enclomiphene ^[2].

Regulatory record

On September 18, 2026 the FDA issued Empower a warning letter addressed to its 503A pharmacy at 7601 N. Sam Houston Pkwy W., Houston, following an inspection from November 3 to 14, 2025 ^[4]. The letter says Empower regularly compounded what the FDA calls essentially copies of approved drugs — tirzepatide with niacinamide and semaglutide with cyanocobalamin. Prescriber statements of a “significant difference” were either missing or repeated word for word across many records, which the FDA says suggests they were pre-generated for the prescriber to select rather than written for an individual patient.

The letter adds, as a general point, that third-party technology platforms offering prescribers pre-selected menu options for that statement call its individual nature into question. The letter also describes sterile products prepared under insanitary conditions, and treats the copied products as unapproved and misbranded. On the insanitary conditions, the FDA found some of Empower’s corrective actions adequate, could not fully evaluate others and judged some deficient. A warning letter states the agency’s position; it is not a court finding, and Empower had fifteen working days to respond.

It was not Empower’s first. On April 2, 2025 the FDA sent two warning letters, one to each Houston site, both about sterile production.

The letter to the 503A pharmacy, after an inspection from September 24 to October 4, 2024, found environmental monitoring that did not sample the critical area of the filling line, media fills not run under the most challenging conditions, and filling-line parts in the ISO 5 area that were not sterilized ^[5].

The letter to the 503B outsourcing facility, after an inspection in August 2024, found microbial contamination in the ISO 5 area without an adequate evaluation of the products affected, airflow studies not run under working conditions and CGMP failures. It also noted the recall of a pyridoxine injection lot and described several findings as repeat violations already discussed with Empower at a May 2023 regulatory meeting ^[6]. An earlier letter to the outsourcing facility, dated October 15, 2021, concerned labels without adverse-event reporting information, incomplete reports of the products it compounded and inadequate adverse-event procedures ^[7].

Separately, the FDA 503B list shows Empower’s Houston outsourcing facility as last inspected on November 14, 2025, with a Form 483 and an action status of “Open” as of the list’s May 2026 update ^[1]. A Form 483 records an investigator’s observations; it is not, by itself, a final finding of violation. All four letters are listed in our register of warning letters to compounding pharmacies.

The read

A high-volume, dual-status operator with a broad GLP-1/peptide/HRT catalog and genuine 503B registration. The 2026 warning letter is aimed at the 503A side, and at compounded tirzepatide and semaglutide sold with an added ingredient. It is the fourth since 2021, and the two 2025 letters were about sterile production at both sites. If your prescription is filled by Empower, the letter is worth reading in full.

References

1. FDA — Registered Outsourcing Facilities (503B) list. (accessed 2026-07-01)
2. Empower Pharmacy — official site. (accessed 2026-07-01)
3. ACHC / PCAB accredited-organization directory. (accessed 2026-07-01)
4. FDA — Warning letter to Empower Clinic Services, LLC dba Empower Pharmacy, MARCS-CMS 738238, September 18, 2026. (accessed 2026-10-21)
5. FDA — Warning letter to Empower Clinic Services, LLC dba Empower Pharmacy (503A), MARCS-CMS 700964, April 2, 2025. (accessed 2026-10-21)
6. FDA — Warning letter to Empower Clinic Services, LLC dba Empower Pharma (503B), MARCS-CMS 700962, April 2, 2025. (accessed 2026-10-21)
7. FDA — Warning letter to Empower Clinic Services, LLC dba Empower Pharmacy (503B), case 613792, October 15, 2021. (accessed 2026-10-21)